Allergan Seeks To Extend Botox Use To Overactive Bladder
This article was originally published in The Pink Sheet Daily
During an R&D day March 28, Allergan highlighted its growth strategy for Botox, which includes expansion into new indications like overactive bladder; the company submitted an sBLA for the indication.
You may also be interested in...
Astellas is tasked with introducing a new product into the already crowded overactive bladder market now that it has gained approval for the beta-3 antagonist mirabegron in the U.S.
The agency raised issues related to the chemistry, manufacturing and controls section of the dihydroergotamine NDA, as well as concerns stemming from inspection of a third-party manufacturing facility, the company says.
Deal with Allergan focuses on detailing to neurologists and pain specialists, leaving MAP free to do other co-promotion deals.